NCT03916744 2023-03-10
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Completed
Genentech, Inc.
INSYS Therapeutics Inc
INSYS Therapeutics Inc
INSYS Therapeutics Inc